Skip to main content

Alzheimer’s Amyloid-Clearing Monoclonal Antibody Drug Lecanemab Shows Positive Results, Poised for FDA Approval

This shows pillsLecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.

from Neuroscience News https://ift.tt/GM6Ke0F
Labels:

Comments

Post a Comment

Popular posts from this blog

Reading Minds to Understand Human Tool Use

Combining brain imaging data with machine learning, researchers make new discoveries about how the brain controls the hand. The findings could lead to the development of more advanced neuroprosthetics. from Neuroscience News https://ift.tt/3tv7BbC
Post a Comment
Read more

Rethinking the Link Between Cannabinoids and Learning

Disrupted cannabinoid signaling impairs learning by altering behavioral states. from Neuroscience News https://ift.tt/2Hrmr0g
Post a Comment
Read more